Markus Peck-Radosavljevic
Overview
Explore the profile of Markus Peck-Radosavljevic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
244
Citations
7711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gairing S, Mildenberger P, Gile J, Artusa F, Scheiner B, Leyh C, et al.
JHEP Rep
. 2025 Mar;
7(3):101295.
PMID: 40059970
Background & Aims: Immunotherapy with atezolizumab and bevacizumab (a + b) has improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the outcome for individual patients is highly...
2.
Scheiner B, Kang B, Balcar L, Radu I, Reiter F, Adzic G, et al.
Hepatology
. 2024 Dec;
PMID: 39643944
Background And Aims: The outcome of patients with HCC who achieved complete response (CR) to immune-checkpoint inhibitor (ICI)-based systemic therapies is unclear. Approach And Results: Retrospective study of patients with...
3.
Daza J, Soares Bezerra L, Santamaria L, Rueda-Esteban R, Bantel H, Girala M, et al.
Ann Hepatol
. 2024 Aug;
30(1):101537.
PMID: 39147133
Introduction And Objectives: Autoimmune liver diseases (AILDs) are rare and require precise evaluation, which is often challenging for medical providers. Chatbots are innovative solutions to assist healthcare professionals in clinical...
4.
Peck-Radosavljevic M, Hucke F
Aliment Pharmacol Ther
. 2024 Jul;
60(3):401-402.
PMID: 38984975
No abstract available.
5.
Hucke F, Emmer H, Emmer R, Hucke M, Bota S, Furstner M, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958389
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths and remains a major burden on healthcare systems worldwide. The incidence of HCC continues to rise globally,...
6.
Lange C, Trebicka J, Gerbes A, Canbay A, Geier A, Merle U, et al.
Liver Int
. 2023 Aug;
43(11):2503-2512.
PMID: 37602977
Background And Aims: Data on number of patients with cirrhosis in Germany are limited. We therefore aimed to estimate prevalence, comorbidities, mortality, utilization of healthcare resources and costs of patients...
7.
Toyoda H, Kanneganti M, Melendez-Torres J, Parikh N, Jalal P, Pinero F, et al.
Clin Gastroenterol Hepatol
. 2023 Jul;
22(1):72-80.e4.
PMID: 37442316
Background & Aims: Widespread use of direct-acting antivirals for hepatitis C virus infection has been paralleled with increased numbers of patients with hepatocellular carcinoma (HCC) after achieving sustained virologic response...
8.
Mandorfer M, Aigner E, Cejna M, Ferlitsch A, Datz C, Grater T, et al.
Wien Klin Wochenschr
. 2023 Jun;
135(Suppl 3):493-523.
PMID: 37358642
The Billroth IV consensus was developed during a consensus meeting of the Austrian Society of Gastroenterology and Hepatology (ÖGGH) and the Austrian Society of Interventional Radiology (ÖGIR) held on the...
9.
Mosconi C, ORourke J, Kloeckner R, Sturm L, Golfieri R, Celsa C, et al.
Cardiovasc Intervent Radiol
. 2023 Feb;
46(4):449-459.
PMID: 36849836
Purpose: Textbook Outcome (TO) is inclusive of quality indicators and it not been provided for trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Materials And Methods: Data on treatment-naïve HCC patients...
10.
Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, et al.
JHEP Rep
. 2022 Dec;
5(1):100620.
PMID: 36578451
Background & Aims: We investigated the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with hepatocellular carcinoma (HCC) who received ICI-based therapies in a previous systemic line....